Center-Authored Papers

Filters: Author is Morgan, Cecilia  [Clear All Filters]
2008
Morgan C, Marthas M, Miller C, Duerr A, Cheng-Mayer C, Desrosiers R, Flores J, Haigwood N, Hu S-lok, Johnson PR et al..  2008.  The use of nonhuman primate models in HIV vaccine development.. PLoS medicine. 5(8):e173.
2010
Peiperl L, Morgan C, Moodie Z, Li H, Russell N, Graham BS, Tomaras GD, De Rosa SC, McElrath MJ.  2010.  Safety and immunogenicity of a replication-defective adenovirus type 5 HIV vaccine in Ad5-seronegative persons: a randomized clinical trial (HVTN 054).. PloS one. 5(10):e13579. Abstract
2011
Churchyard GJ, Morgan C, Adams E, Hural J, Graham BS, Moodie Z, Grove D, Gray G, Bekker L-G, McElrath MJ et al..  2011.  A Phase IIA Randomized Clinical Trial of a Multiclade HIV-1 DNA Prime Followed by a Multiclade rAd5 HIV-1 Vaccine Boost in Healthy Adults (HVTN204).. PloS one. 6(8):e21225. Abstract
Koblin BA, Casapia M, Morgan C, Qin L, Wang ZM, Defawe OD, Baden L, Goepfert P, Tomaras GD, Montefiori DC et al..  2011.  Safety and Immunogenicity of an HIV Adenoviral Vector Boost after DNA Plasmid Vaccine Prime by Route of Administration: A Randomized Clinical Trial.. PloS one. 6(9):e24517. Abstract
Baden LR, Blattner WA, Morgan C, Huang Y, Defawe OD, Sobieszczyk ME, Kochar N, Tomaras GD, McElrath MJ, Russell N et al..  2011.  Timing of Plasmid Cytokine (IL-2/Ig) Administration Affects HIV-1 Vaccine Immunogenicity in HIV-Seronegative Subjects.. The Journal of infectious diseases. 204(10):1541-1549. Abstract
De Rosa SC, Thomas EP, Bui J, Huang Y, DeCamp A, Morgan C, Kalams SA, Tomaras GD, Akondy R, Ahmed R et al..  2011.  HIV-DNA Priming Alters T Cell Responses to HIV-Adenovirus Vaccine Even When Responses to DNA Are Undetectable.. Journal of immunology (Baltimore, Md. : 1950). 187(6):3391-3401. Abstract
2013
Koblin BA, Metch B, Novak RM, Morgan C, Lucy D, Dunbar D, Graham P, Swann E, Madenwald T, Escamilia G et al..  2013.  Feasibility of identifying a cohort of US women at high risk for HIV infection for HIV vaccine efficacy trials: longitudinal results of HVTN 906.. Journal of acquired immune deficiency syndromes (1999). 63(2):239-44. Abstract
Quinn KM, Da Costa A, Yamamoto A, Berry D, Lindsay RWB, Darrah PA, Wang LS, Cheng C, Kong W-P, Gall JGD et al..  2013.  Comparative Analysis of the Magnitude, Quality, Phenotype, and Protective Capacity of Simian Immunodeficiency Virus Gag-Specific CD8+ T Cells following Human-, Simian-, and Chimpanzee-Derived Recombinant Adenoviral Vector Immunization.. Journal of immunology (Baltimore, Md. : 1950). 190(6):2720-35. Abstract
2015
Williams WB, Liao H-X, Moody AM, Kepler TB, Alam MS, Gao F, Wiehe K, Trama AM, Jones K, Zhang R et al..  2015.  Diversion of HIV-1 vaccine-induced immunity by gp41-microbiota cross-reactive antibodies.. Science (New York, N.Y.). Abstract
Koblin BA, Grant S, Frye V, Superak H, Sanchez B, Lucy D, Dunbar D, Graham P, Madenwald T, Escamilia G et al..  2015.  HIV Sexual Risk and Syndemics among Women in Three Urban Areas in the United States: Analysis from HVTN 906.. Journal of urban health : bulletin of the New York Academy of Medicine. Abstract
Fuchs JD, Bart P-A, Frahm N, Morgan C, Gilbert PB, Kochar N, De Rosa SC, Tomaras GD, Wagner TM, Baden LR et al..  2015.  Safety and Immunogenicity of a Recombinant Adenovirus Serotype 35-Vectored HIV-1 Vaccine in Adenovirus Serotype 5 Seronegative and Seropositive Individuals.. Journal of AIDS & clinical research. 6(5) Abstract
Jin X, Morgan C, Yu X, De Rosa S, Tomaras GD, Montefiori DC, Kublin J, Corey L, Keefer MC.  2015.  Multiple factors affect immunogenicity of DNA plasmid HIV vaccines in human clinical trials.. Vaccine. 33(20):2347-53. Abstract
Walsh SR, Moodie Z, Fiore-Gartland AJ, Morgan C, Wilck MB, Hammer SM, Buchbinder SP, Kalams SA, Goepfert PA, Mulligan MJ et al..  2015.  Vaccination with heterologous HIV envelope sequences and heterologous adenovirus vectors increases T cell responses to conserved regions (HVTN 083).. The Journal of infectious diseases. Abstract
2016
Lhomme E, Richert L, Moodie Z, Pasin C, Kalams SA, Morgan C, Self S, De Rosa SC, Thiébaut R.  2016.  Early CD4+ T Cell Responses Are Associated with Subsequent CD8+ T Cell Responses to an rAd5-Based Prophylactic Prime-Boost HIV Vaccine Strategy.. PloS one. 11(4):e0152952. Abstract
Hayes PJ, Cox JH, Coleman AR, Fernandez N, Bergin PJ, Kopycinski JT, Nitayaphan S, Pitisuttihum P, de Souza M, Duerr A et al..  2016.  Adenovirus-based HIV-1 vaccine candidates tested in efficacy trials elicit CD8+ T cells with limited breadth of HIV-1 inhibition.. AIDS (London, England). 30(11):1703-1712. Abstract